These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28655794)

  • 1. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
    Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
    Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
    [No Abstract]   [Full Text] [Related]  

  • 2. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM; Harris RJ; Woodworth DC; Leu K; Zaw O; Mason WP; Sahebjam S; Abrey LE; Aftab DT; Schwab GM; Hessel C; Lai A; Nghiemphu PL; Pope WB; Wen PY; Cloughesy TF
    Neuro Oncol; 2017 Jan; 19(1):89-98. PubMed ID: 27580889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
    Ellingson BM; Aftab DT; Schwab GM; Hessel C; Harris RJ; Woodworth DC; Leu K; Chakhoyan A; Raymond C; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Sep; 20(10):1411-1418. PubMed ID: 29660005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
    Ellingson BM; Patel K; Wang C; Raymond C; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Schlossman J; Rizvi S; Cohen YC; Lowenton-Spier N; Minei TR; Shmueli SF; Wen PY; Cloughesy TF
    Neurooncol Adv; 2021; 3(1):vdab082. PubMed ID: 34377989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
    Kurokawa R; Baba A; Kurokawa M; Capizzano A; Hassan O; Johnson T; Ota Y; Kim J; Hagiwara A; Moritani T; Srinivasan A
    AJNR Am J Neuroradiol; 2022 Feb; 43(2):202-206. PubMed ID: 35058300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Schell M; Pflüger I; Brugnara G; Isensee F; Neuberger U; Foltyn M; Kessler T; Sahm F; Wick A; Nowosielski M; Heiland S; Weller M; Platten M; Maier-Hein KH; Von Deimling A; Van Den Bent MJ; Gorlia T; Wick W; Bendszus M; Kickingereder P
    Neuro Oncol; 2020 Nov; 22(11):1667-1676. PubMed ID: 32393964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
    Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
    J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.
    Patel KS; Yao J; Raymond C; Yong W; Everson R; Liau LM; Nathanson D; Kornblum H; Wang C; Oughourlian T; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Sci Rep; 2020 Sep; 10(1):14819. PubMed ID: 32908231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
    J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
    Ellingson BM; Hagiwara A; Morris CJ; Cho NS; Oshima S; Sanvito F; Oughourlian TC; Telesca D; Raymond C; Abrey LE; Garcia J; Aftab DT; Hessel C; Rachmilewitz Minei T; Harats D; Nathanson DA; Wen PY; Cloughesy TF
    Clin Cancer Res; 2023 Oct; 29(20):4186-4195. PubMed ID: 37540556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
    Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma.
    Kondo M; Uchiyama Y
    J Neuroradiol; 2018 Jul; 45(4):236-241. PubMed ID: 29274693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
    Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
    Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.